Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 82. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Diversity and inclusion in neurosurgery4146
Score fluctuation might be associated with a higher placebo rate in the RAISE trial917
The hidden unity of the mind618
Treatment of asymptomatic carotid stenosis in SPACE-2602
With thanks to our peer reviewers in 2022587
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply566
Correction to Lancet Neurol 2025; 24: 65–76443
The reality of multiple sclerosis assessment in middle-income countries428
Disparities in neurosurgical care for traumatic brain injury395
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial372
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics363
Healthy brain in a healthy body358
From film to philanthropy345
The challenge of pregnancy in women with multiple sclerosis340
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease336
The African Dementia Consortium328
Global burden of stroke: dynamic estimates to inform action306
Women in Neurosurgery: breaking barriers265
Extended-interval dosing of natalizumab in NOVA – Authors' reply250
Medieval treatment of epilepsy in England233
A neurological journey to save lives in Haiti233
Lightning progress in child neurology in the past 20 years230
Tanuja Chitnis: on role models, family, and multiple sclerosis229
Spiralling towards an ending227
Dancing with paper217
Anatomy embroiders function in Purkinje cells211
Malformations of cortical development as models of altered brain excitability206
Maeike Zijlmans194
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation183
Vittorio Marchi's staining183
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr180
The wisdom of our mentors: clinical pearls in movement disorders179
Pseudomedicine for sports concussions in the USA175
Transforming amyotrophic lateral sclerosis into a liveable disease170
Elevating the wellbeing of neurologists167
Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke166
Licence to practise162
CGRP-targeted drugs for migraine: still many uncertainties158
Fetal exposure to antiseizure medications: reassurance and concerns157
Elisaveta Sokolov156
Journey down memory lane148
Sex, gender, and the cost of neurological disorders148
V Wee Yong: a journey of rediscovery147
Giuseppe Citerio's neurocucina141
Form and function in the brain138
Tatyana Shelkovnikova137
The social network of functional neurological disorder137
COP27 Climate Change Conference: urgent action needed for Africa and the world134
A new classification for diagnosis of optic neuritis133
The evolving paradigm of Alzheimer's disease diagnosis132
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease – Authors' reply131
Application of diagnostic criteria for optic neuritis130
Chronic effects of inflammation on tauopathies126
Multiple sclerosis: two decades of progress123
α-synuclein seed amplification in Parkinson‘s disease121
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage119
Appropriate selection of participants for clinical trials in epilepsy118
A neurotransmitter with a fascinating story113
Forging ahead in haemorrhagic stroke research113
What we remember111
Association of Pick's disease with the MAPT H2 haplotype110
PROMISE of low-cost immunosuppressants for myasthenia gravis108
The predictive value and clinical use of the neurological pupillary index – Authors' reply103
Monitoring patients with severe traumatic brain injury102
Innovation in the prevention of neurological diseases101
A contentious FDA ruling for Alzheimer's disease100
Huntington's disease: disappointments and new beginnings99
Dementia care: beyond a diagnosis99
Climate change and neurology: time to talk and to act96
Lessons and future directions for GBA1-targeting therapies94
Georgios Tsivgoulis: in top gear93
Intracranial pressure monitoring and unfavourable outcomes93
20th Anniversary photography competition: neurology for zoomers90
Leriglitazone: frustration and hope in adrenoleukodystrophy88
Headache in 2021: clinical, biological, and genetic advances88
Intra-arterial bone marrow mononuclear cells for stroke86
The shortage of thrombolytics for stroke: a call for action85
Traumatic brain injury advances since 2017: what has changed?85
A disease-specific therapy in facioscapulohumeral muscular dystrophy85
Ischaemic stroke in 2024: progress on multiple fronts84
Jules Froment's neurological statuettes83
Reconsidering prourokinase for acute ischaemic stroke83
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial82
Correction to Lancet Neurol 2024; 23: 393–40382
0.13215494155884